Cosmo Pharmaceuticals N.V. (C43.F)
| Previous Close | 72.00 |
| Open | 71.50 |
| Bid | 72.50 x 11000 |
| Ask | 74.50 x 8000 |
| Day's Range | 71.50 - 71.50 |
| 52 Week Range | 35.00 - 77.00 |
| Volume | |
| Avg. Volume | 30 |
| Market Cap | 1.158B |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | 108.33 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.00 (2.78%) |
| Ex-Dividend Date | May 28, 2024 |
| 1y Target Est | N/A |
- Newsfile
Cosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - April 29, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that the company has been granted extension until 31 May 2024 to publish its 2023 annual report and to file such report with SIX Exchange Regulation AG. ...
- Newsfile
Cosmo Announces Leadership Changes
Ad hoc announcement pursuant to Art. 53 LR Giovanni Di Napoli appointed as new CEO effective from 24 May 2024. Current CEO Alessandro Della Chà to be appointed ...
- Newsfile
Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care
Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology, presented at the Genius Summit 2024 the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system ...
